A multicentre observational registry study of chemoradiotherapy followed by durvalumab in limited stage small cell lung cancer

A multicentre observational registry study of chemoradiotherapy followed by durvalumab in limited stage small cell lung cancer - TSUBAKI study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060353

Enrollment

225

Registered

2026-01-20

Start date

2026-02-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

limited stage small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.18 years or older at time of diagnosed as LS-SCLC 2.Pathologically diagnosed as SCLC by tissue or cytology after 27th March 2025 3.Patients who have started to receive CRT (cCRT or sCRT) as 1st line treatment for SCLC 4.Provided written informed consent (for deceased patients, optout will be applicable, if accepted at the site and approved by Ethics Committee)

Exclusion criteria

Exclusion criteria: 1.Patients with any other prior treatment including surgery for SCLC 2.Patients participating in clinical trials as 1st line treatment for SCLC 3.Patients pathologically diagnosed as large cell neuroendocrine carcinoma 4.Patients with multiple cancer at the start time of 1st line treatment 5.Patients diagnosed with SCLC after tissue transformation from NSCLC

Design outcomes

Primary

Measure	Time frame
Analysis population is LS-SCLC patients who are treated with cCRT followed by durvalumab. Mmedian rwPFS, and rwPFS rates at 18 months and 24 months.	—

Countries

Japan

Contacts

Public ContactYuko Hayashi

AstraZeneca K.K. Evidence & Observational Research, Medical

yuko.hayashi1@astrazeneca.com06-4802-3600

Outcome results